Appointments Tel: 0 (+44) 1625 581781 Logo
» Spire Manchester Hospital » Private Patient Centre » London Vision Clinic

Professor Paulo E. Stanga

Prof. Paulo E. Stanga Prof. Paulo E. Stanga is a Consultant Ophthalmologist and Vitreoretinal Surgeon for the Manchester Royal Eye Hospital, Professor of Ophthalmology and Retinal Regeneration for the University of Manchester and Director of the Manchester Vision Regeneration (MVR) Lab at NIHR/Wellcome Trust Manchester CRF.

Prof. Stanga is a Member of the Scientific Committee of the Royal College of Ophthalmologists (RCOphth) and President of the Ophthalmic Imaging Association (OIA).

Previous appointments include: Lecturer in Ophthalmology for the University of Liverpool, Vitreoretinal Fellow at the Royal Liverpool University Hospital, Medical Retina Fellow at Moorfields Eye Hospital and Retina Research Fellow, New York Hospital, Cornell University Medical College, New York, USA.

Prof. Stanga specialises in vitreo-retinal disorders that require either medical or surgical treatment. Since 1993, Prof. Stanga has worked in the development and application of new outpatient and surgical therapies and technologies such as retrobulbar Interferon alpha-2a, genetics of AMD, retinal pigment epithelium translocation surgery, macular translocation surgery, micropulse diode and Pascal® laser photocoagulation, Time and Spectral Domain and Swept-Source (DRI-OCT1 Atlantis®) optical coherence tomography (OCT), wide-angle (Optos®) fundus fluorescein angiography and fundus autofluorescence technology, antiangiogenic intravitreal drugs and high speed phaco/vitrectomy surgical systems.

His current research interests are in the pharmacological, surgical and laser treatment of proliferative diabetic retinopathy and macular oedema, laser-tissue interaction, electronic retinal implants for artificial vision, non-cutter based high-speed vitrectomy, laser cataract and robotic surgery.

Prof. Stanga introduced OCT into the clinical setting in the UK in 1998 and Pascal Laser into the EU in 2006, developing new retinal laser photocoagulation techniques/strategies for the treatment of Diabetic Retinopathy. Prof Stanga has also pioneered Swept-Source OCT having introduced it into the EU in 2012.

As a result of some of the previously mentioned this research, the Manchester Royal Eye Hospital/UoM are now one of the world leaders in this field. Some of this research in the treatment of diabetic retinopathy is now listed in F1000 and recommended as being of special significance in its field.

Prof Stanga is the Manchester PI for the Argus II (Bionic Eye) 10-centre international trial on the epiretinal electronic implant for blindness in Retinitis Pigmentosa, having operated upon and presented at international meetings the results on the first patients in the trial to achieve word-reading, colour perception or face detection capability with the implant. Prof. Stanga has now set-up a Manchester-only Pilot Study of the Argus II system in Age-Related Macular Degeneration and is the Principal Investigator for this study.

Prof. Stanga has also participated in the development and assessment of new Imaging/Treatment modalities: wide-angle retinal angiography and fundus autofluorescence imaging, adaptive optics imaging of photoreceptors and retinal pigment epithelium, intraoperative optical coherence tomography vitreoretinal imaging, slit-lamp fundus autofluorescence, slit-lamp retinal laser photocoagulation with simultaneous fundus autofluorescence and OCT imaging, amongst others.

Since 2004, Prof. Stanga has secured the equivalent of a total in excess of £2,000,000 in research grant income, research fellow and trial coordinator’s salary and research equipment. The income comes from NHS/NIHR and is therefore held in CMFT.

Prof. Stanga has set up the Manchester Vision Regeneration (MVR) Lab and an independent Retinal Clinical-Research Fellowship Program.

Prof. Stanga has established collaborations with, amongst others: Universities of Cornell, Heidelberg and Stanford , Dohenny Eye Institute-University of Southern California, Kings College Hospital, Moorfields Eye Hospital and University College London.

In 2010, Prof. Stanga and Mr Susmito Biswas established one of only two national Regional Paediatric Vitreoretinal Services. They regularly carry out a joint Paediatric Vireoretinal Clinic.

Prof. Stanga is involved in the Undergraduate/Postgraduate Teaching of Medical, PhD and Optometry Students, Nurses, Orthoptists, Ophthalmology and Vision Sciences MSc. He is Accredited Trust Educational Supervisor providing clinical and surgical training for F2, SpR and VR Fellow at any given time and lectures to the GP and Optometric community.

Prof. Stanga and two of his colleagues at the Manchester Royal Eye Hospital are currently setting up a retinal laser training program for SpR and Fellows.

Prof. Stanga has chaired several international meetings, amongst others and in Manchester: the British and Eire Vitreoretinal Association (BEAVRS) Annual Meeting in 2004 and the Tubingen Retinal Detachment Course and Manchester Retina Course in 2009. In 2014, he chaired the Imaging Day during the MREH Bicentenary celebrations as well as the Retina Day and the Retinal Imaging Symposium and during the Annual Meeting of the Royal College of Ophthalmologists.

As a marker of his national standing, it can be mentioned that Prof. Stanga has been invited by the Royal College of Ophthalmologists in 2010 be a member of the panel of Key Opinion Leaders tasked with updating the National Diabetic Retinopathy College Guidelines and to chair the RCOphth Annual Vitreoretinal Update Seminar. The RCOphth has also invited Prof. Stanga to chair the Retinal Imaging Symposium for its 9th consecutive year as well as the Retina Day during its 2016 Annual Meeting.

Prof. Stanga is a frequent Invited Speaker at national and international meetings representing the MREH, MVR Lab/NIHR Wellcome Trust Manchester CRF and the University of Manchester.

Prof. Stanga is PI on several industry-sponsored trials and Sientific Advisor to several commercial companies that develop pharmacological therapies, diagnostic or therapeutic equipment.

NHS managerial experience at MREH/CMFT include: Associate Head of Ophthalmology Division (2005-2007), Chairman Theatre Users Committee (2005-2008), Laser Safety representative (2005-present), Member of the MREH Diabetic Retinopathy Management Committee (2013-present), Chair of the Laser Safety Sub-Committee for the University of Manchester (2013-present), MREH Lead for Retinal Laser Services (2014-present) and Chair of the MREH Research Steering Committee (2014-present)

Some of Prof. Stanga’s accolades include: Award For Outstanding Contribution to Ophthalmology in Singapore (Singapore, 2006), Award in Appreciation for Support and Far Reaching Contributions at the NGH Eye Institute (Singapore, 2008), American Academy of Ophthalmology Achievement Award (USA, 2011), Outstanding Personality in Science by the City Council (Legislatura Portena) of the city of Buenos Aires (Argentina, 2012), Award for Outstanding Contribution to Retinology in Poland (Krakov, 2014)